NICE Clears Botox For Chronic Migraine, With Therapy “Stopping Rules”
This article was originally published in The Pink Sheet Daily
With rules in place about when to stop therapy, the U.K.'s National Institute for Health and Clinical Excellence clears Allergan's botulinum toxin, Botox for use as prophylaxis in patients with chronic migraine and who have tried other therapies.
You may also be interested in...
The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
The U.K.’s National Institute for Health and Clinical Excellence is asking for a further cost-effectiveness analysis of Roche’s Tarceva to weigh against the cost effectiveness of AstraZeneca’s Iressa.